AstraZeneca scored a victory earlier this month after a Delaware district court ruled that Nexium's distinctive purple hue protects it from copycat competitors. Now Dr. Reddy's is claiming that AstraZeneca not only knew about but also allowed sales of its purple Nexium generics before filing its recent suit, breaking the terms of a previous settlement between the two companies.
Cambridge, MA's Bind Therapeutics announced that patient administration of its Accurins nanoparticles has commenced in the trial of an AstraZeneca cancer candidate. Under the terms of the 2013 partnership with the Big Pharma, Bind earns a milestone payment of $4 million.
AstraZeneca has unveiled a clutch of deals to add to the technological capabilities of its new R&D hub in Cambridge, U.K. The agreements will equip the site with robots to carry out high-throughput screening, sound wave tools to dispense compounds and software to share data with external partners.
After finally turning back the long-running takeover attempt by Mylan, Perrigo assured shareholders they could expect "industry-leading future growth prospects." In its first move toward delivering on that promise, the OTC specialist said today it will buy the U.S. rights to AstraZeneca's Crohn's disease drug Entocort.
AstraZeneca has been duking it out with Dr. Reddy's Laboratories over generic Nexium, winning a round last week after a Delaware district judge put the kibosh on sales of Dr. Reddy's generics and said that Nexium's distinctive purple hue protected it from copycat competitors. But Dr. Reddy's isn't going down without a fight.
AstraZeneca has struck a deal to develop robots for use in the high-throughput screening of compounds. The agreement with HighRes Biosolutions positions the Big Pharma to put its new R&D facility at the forefront of application of robotics to drug discovery and development.
AstraZeneca and Sanofi have exchanged 210,000 compounds from their respective libraries in a no-cash, no-strings-attached deal. The agreement gives scientists at both companies free rein to research and develop compounds shared by the other, without having to pay fees or steer clear of certain therapeutic areas.
AstraZeneca unveiled its pricing plan for the new targeted lung cancer pill Tagrisso that won early FDA approval Friday: $12,750 per month, or $153,000 for a full year of treatment. That's on par with other targeted cancer pills, including the company's own Iressa, a spokeswoman tells Reuters.
AstraZeneca is teaming up with Cambridge, MA-based Cerulean, launching a combo study that marries the biotech's nano-polymer drug conjugate with the pharma giant's Lynparza (the PARP inhibitor olaparib) to test its synergistic effects on tumors. And the National Cancer Institute is stepping in to fund the study and carry it out.
AstraZeneca gained a crucial accelerated FDA approval for its targeted lung cancer drug AZD9291 today, offering tangible evidence of the R&D turnaround CEO Pascal Soriot had promised investors several years ago. And now the drug, to be marketed as Tagrisso, will be put to the market test to see if it can live up to Soriot's $3 billion peak sales estimate while staring down a strong rival in late-stage development at Clovis Oncology.